Announcing-New-Directors-Kayla-Francine-Shannon

Welcoming Kayla, Francine and Shannon to the Board of Directors

MAPS Canada is honoured to announce the appointment of Kayla Breelove Carter, Francine Douglas, and Shannon Smadella to the MAPS Canada Board of Directors. Kayla Breelove Carter Kayla Breelove Carter (MACP, LCT, RCT, CCC, NuPsych., Clinical Traumatologist-TI, Psychedelic Assisted Therapist- IPI) works with individuals and organizations to increase their awareness and understanding of trauma, racial …

Welcoming Kayla, Francine and Shannon to the Board of Directors Read More »

MAPS and Roots to Thrive Partnership cover photo

MAPS Canada announces its new partnership with the groundbreaking non-profit Roots To Thrive

MAPS Canada announces its new partnership with the groundbreaking non-profit Roots To Thrive, Canada’s first and only healthcare practice to legally offer psychedelic-assisted group therapy, research, and training for healthcare professionals. MAPS Canada is pleased to announce its new partnership with the groundbreaking, non-profit healthcare organization Roots To Thrive, based in Nanaimo, BC in collaboration …

MAPS Canada announces its new partnership with the groundbreaking non-profit Roots To Thrive Read More »

Welcoming Sabrina & Rielle to the Board of Directors

MAPS Canada is honoured to announce the appointment of Sabrina Ramkellawan and Dr. Rielle Capler to the MAPS Canada Board of Directors. Sabrina Ramkellawan is president of the Clinical Research Association of Canada, a non-profit organization that provides clinical research education. In addition, she is the COO & Co-Founder of Knowde Group, a female-led contract …

Welcoming Sabrina & Rielle to the Board of Directors Read More »

Announcing Our New Executive Director – Scott Bernstein

September 1st, 2021 MAPS Canada is pleased to announce the appointment of Scott Bernstein as our new Executive Director. A lawyer based in Vancouver, BC, Scott brings over 13 years’ experience in national and international drug policy reform. Prior to joining MAPS Canada, Scott served as Director of Policy for the Canadian Drug Policy Coalition, …

Announcing Our New Executive Director – Scott Bernstein Read More »

MDMA Pharmacology

Introduction Over the past several years, MDMA (also known as Ecstasy/Molly) has been making waves in the realms of drug research and therapy, with many efforts having been largely spearheaded by MAPS. Recognized for its ability to enhance feelings of empathy and bonding among users, research has largely aimed at examining MDMA’s therapeutic potential for …

MDMA Pharmacology Read More »

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial

Objective The Center for Psychedelic and Consciousness Research at Johns Hopkins Medical school in Baltimore conducted a randomized, controlled clinical trial to examine if one or two administrations of psilocybin, in addition to psychological support, could be an effective treatment for patients suffering from major depressive disorder (MDD).  What is Major Depressive disorder? Major depressive …

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial Read More »